BeyondSpring earnings release, May 13, 2026

BeyondSpring Inc. (BYSI) · Form 8-K, Item 2.02 · Filed · SEC filing

BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability

SEED Advances First Molecular Glue Degrader into Clinical Development with Biomarker-Driven Strategy

FLORHAM PARK, N.J., May 13, 2026 (GLOBE NEWSWIRE) --

BeyondSpring Inc.

(NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update highlighting significant scientific and clinical advancements across its pipeline.

“Plinabulin continues to demonstrate the ability to enhance both efficacy and tolerability in ADC-based regimens, supporting its positioning as a potential backbone agent across a rapidly evolving treatment landscape,” said Dr. Lan Huang, Co-Founder, Chair, and Chief Executive Officer of BeyondSpring. “Data presented at AACR 2026 further highlights the expanding value of our pipeline and reinforces our strategy of advancing highly differentiated therapies with the potential to address significant unmet medical needs. We believe Plinabulin has the potential to become a foundational combination agent that unlocks the full clinical and commercial value of ADC therapies.”

Dr. Huang continued, “At SEED, the advancement of ST-01156, a novel RBM39 molecular glue degrader, into clinical development in oncology indications, coupled with a biomarker-driven approach, underscores the strength and scalability of our RITE3™ platform. These milestones reflect disciplined execution across our portfolio and position us to unlock meaningful long-term value through multiple clinical and strategic partnership opportunities.”

Recent Clinical Highlights

Plinabulin:

Expanding Role as a Potentially Foundational Combination Therapy

AACR 2026 data demonstrated that Plinabulin significantly enhances both efficacy and tolerability of topoisomerase inhibitor–based ADC regimens, with or without immune checkpoint inhibitors

Preclinical findings showed:

Improved complete response rate and survival outcomes

Improved tolerability

Enhanced CD8+ T cell / Treg ratio - shifting the tumor immune environment from suppression to attack

These preclinical results suggest Plinabulin’s potential to address key limitations of current ADC therapies, including limited durability and dose-limiting safety concerns, and support Plinabulin’s positioning as a potential backbone agent across a broad range of ADC combination regimens

SEED Therapeutics:

Advancing precision oncology through molecular glue degraders

ST-01156 (RBM39 molecular glue degrader) advanced into Phase 1 clinical development, with the first dose cohort completed

AACR 2026 data demonstrated:

Complete tumor eradication in a neuroblastoma in vivo model

Identification of MYC overexpression and CDKN2A/B deletion as potential predictive biomarkers

This program represents a biomarker-driven precision oncology approach and highlights the productivity of SEED’s proprietary RITE3™ platform for targeted protein degradation

First Quarter Financial Results¹

Continuing operations:

R&D expenses were $1.1 million for the three months ended March 31, 2026 compared to $0.9 million for the three months ended March 31, 2025. The $0.2 million increase was primarily driven by increased drug manufacturing activities to prepare for potential future study initiation, partially offset by lower regulatory filing advisory and personnel expenses

G&A expenses were $1.1 million for the three months ended March 31, 2026 compared to $1.7 million for the three months ended March 31, 2025. The $0.6 million decrease was primarily driven by lower personnel and legal advisory expenses

Net loss was $2.4 million for the three months ended March 31, 2026 compared to $2.6 million for the three months ended March 31, 2025

Cash, cash equivalents, and short-term investments were $7.9 million as of March 31, 2026

Discontinued operations:

Net loss was $4.3 million for the three months ended March 31, 2026, compared to net income of $3.8 million for the three months ended March 31, 2025

Current assets were $5.3 million as of March 31, 2026

Note 1. As a result of BeyondSpring entering into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED, SEED’s operations met the criteria as discontinued operations under ASC 205-20 for financial reporting purposes.

About BeyondSpring

BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for cancers with high unmet need. Its lead asset, Plinabulin, has been studied in over 700 cancer patients and is in late-stage development across multiple cancer indications, with results published in The Lancet Respiratory Medicine. Learn more at beyondspringpharma.com.

About SEED Therapeutics

SEED Therapeutics is a clinical-stage biotechnology company pioneering targeted protein degradation. Its proprietary RITE3™ platform is advancing novel molecular glue degraders across oncology, neurodegeneration, and immunology. SEED collaborates with Eli Lilly and Company and Eisai Co., Ltd., and is advancing its RBM39 degrader into clinical development. Learn more at seedtherapeutics.com.

Investor Contact:

IR@beyondspringpharma.com

Media Contact:

PR@beyondspringpharma.com

Financial statements

Income Statement

Financial Tables to Follow (in thousands)

BEYONDSPRING INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data) (Unaudited) – Three months ended March 31, – 2025 – $BEYONDSPRING INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data) (Unaudited) – Three months ended March 31, – 2026 – $
Operating expensesResearch and development-874-1,076
Operating expensesGeneral and administrative-1,736-1,156
Operating expensesLoss from operations-2,610-2,232
Operating expensesForeign exchange gain, net2950
Operating expensesInterest income178
Operating expensesOther income, net15
Operating expensesLoss before income tax-2,564-2,159
Operating expensesIncome tax expenses-20-192
Operating expensesNet loss from continuing operations-2,584-2,351
Discontinued operationsLoss from discontinued operations-3,232-4,323
Discontinued operationsGain on sale of subsidiary interests6,986
Discontinued operationsNet income (loss) from discontinued operations3,754-4,323
Discontinued operationsNet income (loss)1,170-6,674
Discontinued operationsLess: Net loss attributable to noncontrolling interests from continuing operations-75-132
Discontinued operationsLess: Net loss attributable to noncontrolling interests from discontinued operations-3,232-4,383
Discontinued operationsNet income (loss) attributable to BeyondSpring Inc.4,477-2,159
Earnings (loss) per share, basic and dilutedContinuing operations-0.06-0.05
Earnings (loss) per share, basic and dilutedDiscontinued operations0.17
Earnings (loss) per share, basic and dilutedBasic and diluted earnings (loss) per share0.11-0.05
Weighted-average shares outstandingBasic and diluted40,316,32041,119,803
Other comprehensive loss, net of tax of nil:Foreign currency translation adjustment loss from continuing operations-151-379
Other comprehensive loss, net of tax of nil:Foreign currency translation adjustment loss from discontinued operations-7-47
Other comprehensive loss, net of tax of nil:Comprehensive income (loss)1,012-7,100
Other comprehensive loss, net of tax of nil:Less: Comprehensive loss attributable to noncontrolling interests from continuing operations-130-269
Other comprehensive loss, net of tax of nil:Less: Comprehensive loss attributable to noncontrolling interests from discontinued operations-3,238-4,430
Other comprehensive loss, net of tax of nil:Comprehensive income (loss) attributable to BeyondSpring Inc.4,380-2,401

Balance Sheet

Financial Tables to Follow (in thousands)

BEYONDSPRING INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data) – As of – December 31, 2025 – $BEYONDSPRING INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data) – As of – March 31, 2026 – $ – (Unaudited)
Current assets:Cash and cash equivalents7,7864,036
Current assets:Short-term investments4,7753,827
Current assets:Advances to suppliers227177
Current assets:Prepaid expenses and other current assets71181
Current assets:Current assets of discontinued operations8,0235,283
Current assets:Total current assets20,88213,504
Noncurrent assets:Property and equipment, net166152
Noncurrent assets:Operating right-of-use assets305240
Noncurrent assets:Other noncurrent assets224126
Noncurrent assets:Noncurrent assets of discontinued operations4,3564,384
Noncurrent assets:Total noncurrent assets5,0514,902
Noncurrent assets:Total assets25,93318,406
Current liabilities:Accounts payable363646
Current liabilities:Accrued expenses9381,278
Current liabilities:Current portion of operating lease liabilities320246
Current liabilities:Other current liabilities822937
Current liabilities:Current liabilities of discontinued operations11,1339,263
Current liabilities:Total current liabilities13,57612,370
Noncurrent liabilities:Deferred revenue28,60028,994
Noncurrent liabilities:Other noncurrent liabilities3,9814,239
Noncurrent liabilities:Noncurrent liabilities of discontinued operations3,7663,157
Noncurrent liabilities:Total noncurrent liabilities36,34736,390
Noncurrent liabilities:Total liabilities49,92348,760
Shareholders’ deficitOrdinary shares ($0.0001 par value; 500,000,000 shares authorized; 41,122,320 and 41,119,820 shares issued and outstanding as of December 31, 2025 and March 31, 2026)44
Shareholders’ deficitAdditional paid-in capital375,664375,739
Shareholders’ deficitAccumulated deficit-408,431-410,590
Shareholders’ deficitAccumulated other comprehensive income602360
Shareholders’ deficitTotal BeyondSpring Inc.’s shareholders’ deficit-32,161-34,487
Shareholders’ deficitNoncontrolling interests8,1714,133
Shareholders’ deficitTotal shareholders’ deficit-23,990-30,354
Shareholders’ deficitTotal liabilities and shareholders’ deficit25,93318,406
Full release

Cautionary Note Regarding Forward-Looking Statements... (truncated)n BeyondSpring’s current knowledge, beliefs, and expectations regarding possible future events and are subject to risks, uncertainties, and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including, but not limited to, difficulties raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all; unexpected results from preclinical studies or clinical trials; the risk that preclinical results may not be predictive of clinical results; delays in, or failure to obtain, regulatory approvals; results that do not meet the Company’s expectations regarding the safety, efficacy, clinical utility, or regulatory pathway of the Company’s product candidates; increased competition in the market; the Company’s ability to meet Nasdaq’s continued listing requirements; and other risks described in BeyondSpring’s most recent Form 10-K and subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release, and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Financial Tables to Follow

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · BeyondSpring earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.